Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)

被引:0
|
作者
J Teichmann
U Lange
T Discher
J Lohmeyer
H Stracke
RG Bretzel
机构
[1] Medical Clinic C,Department of Internal Medicine
[2] University of Giessen,III. Medical Clinic
[3] University of Giessen,II. Medical Clinic
关键词
HIV; Hypogonadism; Bone Mineral Density; Calciotropic Hormones;
D O I
暂无
中图分类号
学科分类号
摘要
Alterations of bone metabolism have been observed in numerous studies of HIV-infected patients. Sex steroids are known to profoundly influence bone mass and bone turnover. Hypogonadism is common in HIV-infection. Therefore, we performed a cross sectional study of 80 male HIV-infected patients without wasting syndrome, and 20 healthy male controls, in whom we analyzed urine and serum samples for both calciotropic hormones and markers of bone metabolism and of endocrine testicular function. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry both in the lumbar spine and Ward's triangle of the left hip. None of the patients received highly-active-antiretroviral-therapy (HAART). Compared to eugonadal HIV-infected patients, subjects with hypogonadism (n = 32; 40%) showed statistically significant decrease of serum osteocalcin (p < 0.05) and elevated urinary excretion of crosslinks (p < 0.05). However, we found 13 and 15, respectively, patients with osteopenia (t-score -1.0 to -2.5 SD below normal) of the lumbar spine. The dissociation between bone formation and resorption and the reduction of of BMD (p < 0.05) is stronger expressed in patients with hypogonadism. Habitual hypogonadism appears to be of additional relevance for bone metabolism of male HIV-positive patients prior to HAART.
引用
收藏
相关论文
共 50 条
  • [1] BONE MINERAL DENSITY IN HUMAN IMMUNODEFICIENCY VIRUS-1 INFECTED MEN WITH HYPOGONADISM PRIOR TO HIGHLY-ACTIVE-ANTIRETROVIRAL-THERAPY (HAART)
    Teichmann, J.
    Lange, U.
    Discher, T.
    Lohmeyer, J.
    Stracke, H.
    Bretzel, R. G.
    [J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2009, 14 (02) : 59 - 64
  • [2] Predictors of bone mineral density in human immunodeficiency virus-1 infected children
    Jacobson, DL
    Spiegelman, D
    Duggan, C
    Weinberg, GA
    Bechard, L
    Furuta, L
    Nicchitta, J
    Gorbach, SL
    Miller, TL
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2005, 41 (03): : 339 - 346
  • [3] Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART)
    Bolland, Mark J.
    Grey, Andrew
    Horne, Anne M.
    Briggs, Simon E.
    Thomas, Mark G.
    Ellis-Pegler, Rod B.
    Gamble, Greg D.
    Reid, Ian R.
    [J]. CLINICAL ENDOCRINOLOGY, 2012, 76 (05) : 643 - 648
  • [4] Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1
    Shafer, RW
    Vuitton, DA
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 1999, 53 (02) : 73 - 86
  • [5] HYPOVITAMINOSIS D AND BONE MINERAL DENSITY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED MEN FROM INDIA, WITH OR WITHOUT ANTIRETROVIRAL THERAPY
    Paul, Thomas Vizhalil
    Asha, Hesarghatta Shyamasunder
    Thomas, Nihal
    Seshadri, Mandalam Subramanian
    Rupali, Priscilla
    Abraham, Ooriapadickal Cherian
    Pulimood, Susanne Alexander
    Jose, Arun
    [J]. ENDOCRINE PRACTICE, 2010, 16 (04) : 547 - 553
  • [6] Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART)
    Kumar, N. Sum
    Shashibhushan, J.
    Malappa
    Venugopal, K.
    Vishwanatha, Hugo
    Menon, Mahesh
    [J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2015, 9 (07) : 5 - 8
  • [7] Characteristics of human immunodeficiency virus-1 infected children receiving Highly active antiretroviral therapy: a cross-sectional study
    Badillo, K.
    Prieto, L.
    Toledano, M.
    Guillen, S.
    Alvarez, A.
    Garcia Bermejo, I.
    Ramos Amador, J. T.
    [J]. ANALES DE PEDIATRIA, 2012, 76 (06): : 317 - 323
  • [8] Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART)
    Authier, FJ
    Chariot, P
    Gherardi, RK
    [J]. MUSCLE & NERVE, 2005, 32 (03) : 247 - 260
  • [9] Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy
    Bolland, Mark J.
    Grey, Andrew B.
    Horne, Anne M.
    Briggs, Simon E.
    Thomas, Mark G.
    Ellis-Pegler, Rod B.
    Woodhouse, Andrew F.
    Gamble, Greg D.
    Reid, Ian R.
    [J]. CLINICAL ENDOCRINOLOGY, 2006, 65 (02) : 191 - 197
  • [10] Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection
    Samaras, Katherine
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) : 238 - 245